Clinical Policy Title: Genetic testing for cytochrome P450 polymorphisms
ثبت نشده
چکیده
CP# 02.01.08 Familial polyposis gene testing CP# 02.01.14 Gene expression profile testing for breast cancer CP# 11.04.02 Genetic testing for autism spectrum disorders CP# 02.01.02 Genetic testing for breast and ovarian cancer CP# 02.01.07 Genetic testing for cystic fibrosis CP# 05.01.03 Genetic testing for G1691A polymorphisms Factor V Leiden CP# 04.01.02 Genetic testing for Long QT syndrome (LQTS) CP# 02.01.04 Genetic testing for primary autosomal recessive microcephaly CP# 02.01.09 Genetic testing for rare diseases CP# 13.01.01 Genetic testing for prostate cancer prognosis CP# 09.01.09 Genetic testing in neurology CP# 02.01.18 Genetic testing in sensorineural hearing loss CP# 05.01.04 Molecular analysis for targeted therapy of non-small cell lung cancer CP# 05.01.05 Molecular targeted therapy CP# 02.01.03 Array comparative genomic hybridization testing CP# 02.01.04 Pharmacogenetic testing for cardiac meds CP# 02.01.04 Pharmacogenetic testing for warfarin (Coumadin®) sensitivity
منابع مشابه
Clinical Policy Title: Molecular targeted therapy
CP# 02.01.08 Familial polyposis gene testing CP# 02.01.14 Gene expression profile testing for breast cancer CP# 11.04.02 Genetic testing for autism spectrum disorders CP# 02.01.02 Genetic testing for breast and ovarian cancer CP# 02.01.07 Genetic testing for cystic fibrosis CP# 00.01.03 Genetic testing for cytochrome p450 Polymorphisms (CYP2C19) CP# 05.01.03 Genetic testing for G1691A Polymorph...
متن کاملAssociation between Cytochrome P450 2C19 Gene Polymorphisms and Hematological Malignancies in an Iranian Population
Background: Cytochrome P450 2C19 (CYP2C19) is widely involved in the metabolism of some medications. On the other hand, recent studies have shown the contribution of the CYP2C19 polymorphisms to different malignancies. We aimed to investigate the association between CYP2C19 polymorphism and occurrence of hematological malignancies by comparing the phenotype distribution of this enzyme in patien...
متن کاملAssociation between Cytochrome P450 2 C9 and Vitamin K Epoxide Reductase Complex Subunit 1 Polymorphisms with Warfarin dose among Iranian Patients
Background: Warfarin is a common anticoagulant drug that has a narrow therapeutic index; higher dose causes excessive bleeding and lower dose leads to cerebrovascular clotting and stroke in patients. Genetic factors that have been associated with warfarin response are the genes of cytochrome P450 2C9 (CYP2C9), which metabolize the more active S-enantiomer of warfarin, and vitamin K epoxide redu...
متن کاملGenetic Polymorphisms of CYP2C19 and Resistance to Clopidogrel Therapy among Iranian Patients Suffering from Ischemic Heart Disease
Background: Clopidogrel is a standout amongst the most ordinarily recommended medications to avoid ischemic occasions taking after coronary disorder or stant position. However, impaired responses the therapy as well as resistance to the therapy have also been reported. Genetic variants play an important role in clopidogrel biotransformation of its active metabolite that may subsequently influen...
متن کاملFREQUENCY OF C3435 MDR1 AND A6896G CYP3A5 SINGLE NUCLEOTIDE POLYMORPHISM IN AN IRANIAN POPULATION AND COMPARISON WITH OTHER ETHNIC GROUPS
ABSTRACT Background: It is well recognized that different patients respond in different ways to medications. The inter-individual variations are greater than the intera- individual variations, a finding consistent with the notion that inheritance is a determinant of drug responses. The recent identification of genetic polymorphisms in drug-metabolizing enzymes and drug transporters led to the ...
متن کامل